Matthew Hill

Vice President of Research & Development

Matt Hill is the VP of Research and Development at Evonetix, with overall responsibility for the 100-strong team of technologists; spanning engineering, digital and cloud, and science.

Matt joined Evonetix in 2019, as Head of Mechanical Engineering, after spending 12 years at Cambridge Consultants. He focussed on Programme and Line Management in the UK before taking a secondment to the US to lead the expansion of the Boston site into Industrial and Consumer.

Matt holds a Masters degree in Mechanical Engineering from the University of Durham and is a Chartered Member of the Institution of Mechanical Engineers.

Mammen Eapen

NON-EXECUTIVE DIRECTOR

Mammen joined Cambridge Consultants as Chief Financial Officer in 2005. Cambridge Consultants has since grown from revenues of £17M in 2005 to revenues of £120M in 2021, with offices in the US, Singapore and Japan in addition to its headquarters in Cambridge, United Kingdom.

Prior to this, Mammen was an Executive Director and Regional Finance Director for the Asian business operations of Arthur D Little. He primarily operated from a base in Singapore.

He has also worked in operational and general management roles in both Toronto, Canada and Sydney , Australia.

Mammen graduated with a first class degree in Commerce from the University of Madras, India. He trained and qualified, in 1986, as a Chartered Accountant with Ernst & Young in London, UK.

Michael Daniels

Vice President of Product

Michael Daniels joined Evonetix in March 2021 and brings over 20 years experience of marketing, product management and business development across the biotechnology sector.

His previous roles include Director level positions in Marketing and Product Management at Thermo Fisher Scientific and Arcis Biotechnology, leadership of the Cell and Molecular Research Tools business segment at GE Healthcare and head of Marketing & Business Development at Promega UK.

Michael holds a PhD in Molecular Genetics and Protein Biochemistry from the Department of Biochemistry and Genetics at the University of Newcastle and has also completed numerous professional qualifications and training in marketing, management, and IP law.

Colin McCracken

Chief Executive Officer

Colin brings over 20 years’ experience in commercial and business development roles. Prior to joining Evonetix he was Senior Vice President and Chief Commercial Officer at Fluidigm Corp, where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Company’s global reach. He has delivered commercial success in numerous leadership positions, including Vice President and General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President and Head of European Sales at Life Technologies and National Sales Manager at Qiagen.

As CEO of Evonetix, Colin will focus on building strategic partnerships and customer relationships, ahead of the commercial introduction of the Company’s first benchtop DNA printer.

Matthew Hayes

CHIEF TECHNOLOGY OFFICER

Matthew Hayes is the Chief Technology Officer of Evonetix, and was a founder member of the team that created the company in 2015.

Before joining Evonetix, Matthew was Head of Technology for the Global Medtech Division of Cambridge Consultants. He joined Cambridge Consultants in 2001, and was responsible for the leadership of many of their largest and most technically challenging projects.

Matthew specialises in multi-disciplinary system design, medical device development, ASIC design and opto-electronics. He holds a PhD and MEng in Electronic Engineering, both from Loughborough University.

Malcolm Gates

Vice President of Finance

Malcolm joined Evonetix in June 2021 with over 20 years’ of experience. Malcolm is responsible for a broad portfolio of financial, HR and other matters.

Malcolm was previously Group Finance Director at Cambridge Cognition, an AIM listed public company specialising in brain health, for six years. As well as leading on financial and related matters, Malcolm was the lead business partner to the sales and marketing, operations, and R&D functions. Before these roles, Malcolm had over 15 years’ experience in professional services with PwC. Malcolm has worked globally (being based in the UK and Australia) and also across a range of industries. Malcolm also worked in both the assurance and consultancy practices of PwC. These roles have given Malcolm experience of developing companies as they grow in size and complexity.

Malcolm is a Fellow Chartered Accountant (FCA) of the Institute of Chartered Accountants in England and Wales and has an MA in Geography from the University of Cambridge.

Raquel Sanches-Kuiper

Vice President of Technology

Raquel Sanches-Kuiper was appointed Director of Biology of Evonetix in February 2017.

Raquel is an experienced R&D leader with a track-record of taking new ideas from concept phase to commercialised products in the Next Generation Sequencing (NGS) space.

Before joining Evonetix, Raquel was at Solexa (then Illumina Inc.) from 2002 as a Protein Engineer and major contributor to its disruptive NGS technology. She then moved to leadership roles of global multidisciplinary projects to support product development and introduction of new products. She also acted as a Consultant for projects in collaboration with Genomics England, Technology Development and Applications, and Customer Support.

Prior to that, Raquel was a post-doctoral researcher in the Department of Chemical Engineering and Biotechnology, University of Cambridge, in the area of cancer gene therapy.

Raquel holds a PhD in Molecular and Cell Biology from the Faculty of Medicine, University of Auvergne and a MSci in Biochemistry from the Faculty of Sciences, University of Lisbon.

Jason Pontin

NON-EXECUTIVE DIRECTOR

Jason Pontin is a Partner at DCVC, where his belief that emerging technologies and new scientific insights can solve urgent challenges and expand human possibilities inspires his investments in Deep Tech and life sciences companies. Among his operational responsibilities at DCVC, he helps portfolio companies tell their stories.

He was the first investor in DCVC-backed Totus Medicines, where he is a founding board member, and in Menten.AI. Before joining DCVC, he was a senior partner and senior advisor at Flagship Pioneering in Cambridge, MA, where he worked with the enterprise’s therapeutics and agriculture companies.

Jason was CEO and editor in chief of MIT Technology Review and editor of Red Herring magazine, the bible of the dot.com boom. At MIT, he founded MIT Solve, the Institute’s open innovation platform, which deploys capital and other resources toward solutions to grand challenges; chaired the MIT Enterprise Forum, the Institute’s global entrepreneurial community; and was senior advisor to MIT’s 16th President, Susan Hockfield.

He has written for a range of publications including a column for the New York Times and articles for many other newspapers and magazines like The Economist, The Financial Times, The Boston Globe and The Believer. He still writes, mostly for WIRED. At TED 2013, he delivered a Talk, “Can technology solve our big problems?” which has been seen 1.6 million times.

Jason was raised in Berkeley and on a farm on the North Coast of California, where his family raised game birds for restaurants in the Bay Area. He was educated in the United Kingdom at Keble College, Oxford University, where he was awarded a B.A. and M.A in humanities fields completely unrelated to his investment interests.

Paul Beastall

NON-EXECUTIVE DIRECTOR

Paul Beastall is the Head of Strategy and member of the senior leadership team at Cambridge Consultants. He has experience working in a broad range of roles in start-ups, large corporations, government and consultancy.

Paul specialises in the commercialisation of innovative technology and the impact of technological developments on businesses and society. He works with some of Cambridge Consultants’ largest clients, helping them maximise the value of innovation. He works across a broad range of sectors from telecommunications to consumer products, focusing on the impact of digital platforms to enable new business models.

He holds a masters’ degree in electronic systems engineering from the University of York and is a Fellow of the Institution of Engineering and Technology.

Andrew Briggs

PROFESSOR OF NANOMATERIALS AT THE UNIVERSITY OF OXFORD

Professor Andrew Briggs is Professor of Nanomaterials at the University of Oxford, where his research focuses on materials and techniques for quantum information technologies and investigating vibrational states of nanotubes and charge transport through single molecules in graphene nanogaps. In addition to publishing nearly 600 peer-reviewed scientific papers, he is the author of several books that address scientific issues in the context of a broader humanist debate. His interests include understanding the influence of new technologies and how society views their potential impact on human flourishing. He completed his PhD at the University of Cambridge.

Sir David Klenerman

PROFESSOR OF BIOPHYSICAL CHEMISTRY AT THE UNIVERSITY OF CAMBRIDGE

Professor Sir David Klenerman is Professor of Biophysical Chemistry at the University of Cambridge, where he also earned his PhD. His research focuses on developing quantitative biophysical methods, applied to biology and biomedicine. Prof Klenerman co-developed next-generation DNA sequencing methods that were subsequently commercialised by Solexa (now Illumina), which he also co-founded. He is a Fellow of the Royal Society and The Academy of Medical Sciences and the Royal Society of Chemistry (RSC), and has received numerous awards including a Royal Medal and Interdisciplinary Award of the RSC.

Hermann Hauser

INVESTOR & BOARD OBSERVER

Hermann Hauser, entrepreneur and co-founder of Amadeus Capital Partners, supported the foundation of Evonetix in 2015, together with Cambridge Consultants.

In 40 year career as an entrepreneur and venture capitalist, Hermann has helped start a number of technology companies, including Acorn Computers and its spin-out ARM, as well as Cambridge Silicon Radio and next-generation DNA sequencing technology company Solexa, which became the market leader and was later acquired by Illumina.

Hermann was awarded an Honorary CBE for ‘innovative service to the UK enterprise sector’ in 2001. In 2004, he was appointed a member of the Government Council for Science & Technology. In 2012, he became a Fellow of the Royal Society in recognition of his contribution to the translation of science into business, in 2013 a Distinguished Fellow of BCS, the Chartered Institute for IT, and in 2015 an Honorary Knight Commander (KBE) for services to engineering and industry.

Hermann holds an MA in Physics from Vienna University and a PhD in Physics from the University of Cambridge. He is a Fellow of the Institute of Physics and of the Royal Academy of Engineering, and an Honorary Fellow of King’s College, Cambridge.

Vishal Gulati

NON-EXECUTIVE DIRECTOR

Dr. Vishal Gulati is one of the Europe’s leading digital healthcare investors. Vishal is a qualified physician and chairman of the Digital Health Forum. Over the last decade he has championed deals across areas including diagnostics, devices & biotech. He is currently on the boards of Horizon Discovery PLC and EcoEos. His investments include Napo Pharmaceuticals, Glenmark, Renovo, Phagenesis. He has also held board positions at Psynova Neurotech, Bioscale and Enigma Diagnostics. Previously, Vishal worked at Atlas Venture, The Wellcome Trust and Radiant Capital.

Jim Tananbaum

NON-EXECUTIVE DIRECTOR

Jim Tananbaum is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm founded in 2011 that has $3 billion in assets under management. Jim assembles the people, ideas and money needed to launch products that save lives and improve healthcare. He is always looking for visionaries: men and women with insights into therapeutics, devices, diagnostics or services that could, with the right support, change the world. During the last three decades Jim has been a thought partner for some of the most impactful and fastest growth companies of their generation including: 10x Genomics (NASDAQ: TXG), Amerigroup (NASDAQ: ANTM), and Jazz Pharmaceuticals (NASDAQ: JAZZ).